Promega v. Roche
This article was originally published in The Gray Sheet
Executive Summary
European Patent Office (EPO) in Munich revokes Roche's biotechnology patent '017, which covers components critical to DNA analysis used in polymerase chain reaction (PCR) and gene sequencing, Promega announces May 31. Madison, Wisconsin-based firm, along with BD Corp., New England BioLabs and Bioline, presented data to EPO showing that others had purified the Taq DNA polymerase first and that the recombinant Taq gene was obviously based on prior art. EPO's decision to revoke the patent is consistent with 1999 San Francisco federal court ruling that Roche committed eight separate acts of fraud in obtaining its '818 patent (1"The Gray Sheet" Dec. 13, 1999, p. 16)
You may also be interested in...
Roche To Appeal Native Taq Ruling To Defend Scientific Integrity
Roche Molecular Systems and parent company Hoffman-La Roche intend to appeal a Dec. 7 San Francisco federal district court ruling that the firm's native Taq polymerase patent is "unenforceable" because of inequitable conduct during Cetus Corp.' s patent application process in 1986, Roche said Dec. 8.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.